Compare AbbVie Inc (ABBV) vs Honest Company Inc (HNST) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

HNST trades at $3.94, up 1.03% with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.01, meeting expectations, but maintains negative net income margins. Revenue declined to $371.32M in 2025 from $378M in 2024, though gross margins improved to 33.89%. Operating cash flow strengthened to $15.12M, supporting liquidity. Analyst sentiment is mixed with 30% buy ratings amid ongoing profitability challenges.

The outlook remains cautious due to persistent net losses and revenue volatility. Investment appeal hinges on margin expansion and sustained cash flow generation. Key risks include competitive pressures in personal care and execution on growth initiatives. The stock's elevated P/E of 48.83 suggests high expectations for future earnings recovery.